Teladoc Health, Inc. TDOC

Healthcare SIC 8011 - Services-Offices & Clinics of Doctors of Medicine NAICS Health Care and Social Assistance › Ambulatory Health Care Services derived NYSE

Teladoc Health is the global leader in virtual care. More than 20 years ago, we were founded on a simple, yet revolutionary idea: that everyone should have access to the best healthcare, anywhere in the world on their terms. Our mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. Today, we are transforming virtual care into a catalyst for how better health happens around the world. We connect patients, care providers, healthcare platforms and partners to provide more complete and personalized care. Through our unique technology, breadth of services and depth of clinical expertise, we are delivering and orchestrating care in order to improve health outcomes and reduce healthcare costs around the world.

Last close 6.34 2026-10-23
Market cap $1.15B 2026-06-30 share count
52-week range 4.40 - 9.89

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF4.0x
EV/EBITDA—
Dividend yield—
Diluted EPS-1.14

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S. Revenue
  • International Revenue
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 U.S. Revenue, FY2025: 2.1B (81.9%) 82% U.S. Revenue International Revenue, FY2025: 458.2M (18.1%) 18% International Revenue FY2024 U.S. Revenue, FY2024: 2.2B (84.1%) 84% International Revenue, FY2024: 409.6M (15.9%) 16% FY2023 U.S. Revenue, FY2023: 2.2B (86.0%) 86% International Revenue, FY2023: 364.9M (14.0%) 14%
Region FY2025FY2024FY2023
U.S. Revenue $2.07B $2.16B $2.24B
International Revenue $458.2M $409.6M $364.9M

As the company reported it, from the “Revenue, Deferred Revenue, and Deferred Device and Contract Costs - Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.53B$2.57B$2.60B$2.41B$2.03B$1.09B$553.3M$417.9M$233.3M$123.2M
Cost of revenue ———$744.0M$650.3M$390.8M$184.5M$128.7M$61.6M$32.0M
Gross profit ———$1.66B$1.38B$703.1M$368.8M$289.2M$171.7M$91.2M
R&D $277.9M$307.3M$348.5M$333.6M$311.9M$164.9M$64.6M$54.4M$34.5M$21.8M
SG&A $431.9M$435.5M$464.7M$449.9M$438.0M$506.7M$164.5M$116.9M$79.8M$48.6M
Total operating expenses $2.79B$3.59B$2.85B$16.06B$2.30B$1.60B$633.7M$488.8M$308.7M—
Operating income -$263.0M-$1.02B-$248.6M-$13.65B-$265.6M-$506.4M-$80.4M-$70.9M-$75.4M-$62.7M
Interest expense $19.7M$23.8M$22.3M$21.9M$81.1M$60.0M$29.4M$26.1M$17.5M$2.6M
Pre-tax income -$235.5M-$993.7M-$219.6M-$13.66B-$384.7M-$576.0M-$109.5M-$97.0M-$107.0M-$73.7M
Income tax $35.2M$7.6M$760.0K$3.8M$44.1M$90.9M$10.6M$118.0K$225.0K$510.0K
Net income -$200.3M-$1.00B-$220.4M-$13.66B-$428.8M-$485.1M-$98.9M-$97.1M-$106.8M-$74.2M
EPS, basic -1.14-5.87-1.34-84.60-2.73-5.36-1.38———
EPS, diluted -1.14-5.87-1.34-84.60-2.73-5.36-1.38-1.47-1.93-1.75
Shares, diluted (wtd. avg.) 176.2M170.6M164.6M161.5M156.9M90.5M71.8M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $781.1M$1.30B$1.12B$918.2M$893.5M$733.3M$514.4M$424.0M$42.8M$50.0M
Short-term investments ———$0$2.5M$53.2M$2.7M$54.5M——
Receivables $192.8M$214.1M$217.4M$210.6M$169.0M$169.3M$56.9M$43.6M$27.1M$13.8M
Inventory $38.2M$38.1M$29.5M$56.3M$73.1M$56.5M$0———
Total current assets $1.12B$1.66B$1.49B$1.32B$1.23B$1.06B$588.0M$532.7M$156.2M$82.7M
Property, plant and equipment $27.0M$29.5M$32.0M$29.6M$27.2M$28.6M$10.3M$10.1M$9.0M$7.5M
Goodwill $283.2M$283.2M$1.07B$1.07B$14.50B$14.58B$746.1M$737.2M$498.5M$188.2M
Other intangibles $1.30B$1.43B$1.68B$1.84B$1.91B$2.02B$225.5M$247.4M$159.8M$24.9M
Total assets $2.86B$3.52B$4.39B$4.35B$17.73B$17.76B$1.60B$1.53B$824.4M$303.7M
Accounts payable $48.0M$33.1M$43.6M$47.7M$47.3M$46.0M$9.1M$7.8M$3.9M$2.2M
Short-term debt ————$0$42.6M$0——$2.0M
Total current liabilities $404.7M$941.5M$420.6M$399.8M$331.0M$332.6M$90.2M$62.4M$40.3M$21.1M
Long-term debt —————————$42.4M
Total liabilities $1.47B$2.03B$2.07B———————
Retained earnings -$16.43B-$16.23B-$15.23B-$15.01B-$1.42B-$992.7M-$507.5M-$408.7M-$311.6M-$204.7M
Total equity $1.39B$1.49B$2.33B$2.31B$16.05B$15.88B$1.01B$1.01B$558.9M$230.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $294.4M$293.7M$350.0M$189.3M$194.0M-$53.5M$29.9M-$4.9M-$34.4M-$51.9M
Depreciation and amortisation ———$256.0M$204.2M$69.5M$39.0M$35.6M$19.1M$8.3M
Stock-based compensation $80.4M$146.0M$201.6M$217.9M$302.6M$475.5M$66.7M$43.8M$30.6M$7.7M
Capital expenditure $8.9M$10.8M$11.5M$16.5M$8.5M$4.0M$3.5M$4.0M$2.6M$2.1M
Investing cash flow -$266.0M-$124.1M-$156.3M-$167.7M-$73.0M-$591.0M$25.0M-$257.5M-$448.4M$26.1M
Financing cash flow -$551.7M$8.3M$10.9M$6.5M$40.9M$859.1M$35.1M$645.6M$475.4M$20.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477449-26-000020.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15B -10B -5B 0 5B Revenue, FY2016: 123.2M Gross profit, FY2016: 91.2M Net income, FY2016: -74.2M Revenue, FY2017: 233.3M Gross profit, FY2017: 171.7M Net income, FY2017: -106.8M Revenue, FY2018: 417.9M Gross profit, FY2018: 289.2M Net income, FY2018: -97.1M Revenue, FY2019: 553.3M Gross profit, FY2019: 368.8M Net income, FY2019: -98.9M Revenue, FY2020: 1.1B Gross profit, FY2020: 703.1M Net income, FY2020: -485.1M Revenue, FY2021: 2B Gross profit, FY2021: 1.4B Net income, FY2021: -428.8M Revenue, FY2022: 2.4B Gross profit, FY2022: 1.7B Net income, FY2022: -13.7B Revenue, FY2023: 2.6B Net income, FY2023: -220.4M Revenue, FY2024: 2.6B Net income, FY2024: -1B Revenue, FY2025: 2.5B Net income, FY2025: -200.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $123.2M $233.3M $417.9M $553.3M $1.09B $2.03B $2.41B $2.60B $2.57B $2.53B
Gross profit $91.2M $171.7M $289.2M $368.8M $703.1M $1.38B $1.66B — — —
Net income -$74.2M -$106.8M -$97.1M -$98.9M -$485.1M -$428.8M -$13.66B -$220.4M -$1.00B -$200.3M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8011

TickerCompanyMarket capP/ERevenue growth
HIMS Hims & Hers Health, Inc. $6.42B 54.3x 59.0%
STLN Starling Oncology, Inc. $683.9M — 27.8%
SBC SBC Medical Group Holdings Inc $543.0M 10.6x -15.5%
LFMD LifeMD, Inc. $102.7M 8.5x 25.3%
AIRS Airsculpt Technologies, Inc. $86.5M — -15.8%
CCM Concord Medical Services Holdings Ltd — — 26.6%
BMGL Basel Medical Group Ltd — — —